Press Release: Biograil announces – Sanner Ventures has joined Investor Syndicate

COPENHAGEN, DENMARK, April 30, 2020 – Biograil ApS, a Copenhagen based biotech company developing a unique oral device for delivery of biologics that would otherwise be injected, earlier announced the closing of a seed funding of 3 Million Euro (with potential to expand to 5 Million Euro). Biograil is now happy to have included Sanner Ventures in the Investor Syndicate. The Investor Syndicate is led by German seed investor High-Tech Gründerfonds (HTGF) and includes Danish Megatrend Invest a/s as well as a Swiss Investment group and an experienced Danish private healthcare investor.

Sanner Ventures, parent company of the Sanner Group and a single-family office specializing in new technologies in the area of health and well-being, supports Biograil with an equity investment. The Sanner Group is a world leading manufacturer of moisture protective plastic packaging systems for pharmaceutical, medical and healthcare industries. Beside the investment of Sanner Ventures in Biograil, the Sanner Group provides strong insight in cost effective upscaling of injection molding for commercialization, the technology Biograil uses to manufacture its oral devices. The Sanner Group also has a strong network for packaging supply to a wide spectrum of pharmaceutical companies, which could provide additional strategic value to Biograil.

Biograil CEO Karsten Lindhardt said: “It is great that we continue to be able to attract experienced investors like Sanner Ventures to our Investor Syndicate and we are happy that the investors can add more than financial support to the Biograil business.

Investment Associate at Sanner Ventures Christian Schierholz, who is now an observer in the Board of Directors of Biograil, commented: “Sanner Ventures is glad to now be part of the Investor Syndicate. We are impressed with the technology and team behind Biograil. We look forward to seeing what can be achieved in the future with this unique technology and its large business prospects and ability to make it easier, more convenient and potentially safer for patients to take their medicine for effective treatment of multiple diseases”.

Biograil will use the funds to optimize the design of its delivery device and to advance its ongoing preclinical testing and to plan for a substantial global Series A Funding in Q1 2021.

About Biograil Aps

Biograil is a Danish start-up using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device uses the body’s own peristaltic forces to facilitate the delivery of active substances i.e. biologics efficiently into the gastrointestinal wall. The team behind Biograil is a combination of seasoned entrepreneurs with long experience in creating successful biotech companies as well as R&D executives behind the world’s first injection molded oral tablet approved by the FDA.

About High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge almost 600 startups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry and life sciences.

To date, external investors have injected over EUR 2.5 billion into the HTGF portfolio via more than 1,600 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.


MEGATREND INVEST is a well consolidated provider of capital between investors looking for alternative investments and sustainable start-ups and growth companies seeking capital. Through risk diversification, we provide a high rate of return for investors.

MEGATREND INVEST expect companies to conduct a responsible and sustainable business based on 9 leading megatrends in the world (such as health, biotechnology, etc.) and focus investments on sustainable products and solutions based on the sustainable development goals.

About Sanner Ventures & Sanner Group

As a single-family office and the venture arm of Sanner Group, Sanner Ventures aims to explore new business areas and to invest in early-stage technology companies in the area of health and well-being. Sanner Ventures is devoted to products and solutions that help to protect patient health and facilitate better health outcomes.

Based in Bensheim, Germany, the Sanner Group was founded in 1894 and is now in its fourth generation as a family-owned enterprise. Sanner develops and produces high-quality plastic packaging and drug delivery systems for pharmaceutical, medical and healthcare customers. The group gained international recognition for its desiccant know-how and moisture protection solutions. With more than 500 employees, Sanner is present all over the world, amongst others in Germany, China, India and the U.S. The company produces over two billion plastic injection molded units each year for standard and customized packaging and drug delivery solutions.